<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Family Community Med</journal-id><journal-id journal-id-type="iso-abbrev">J Family Community Med</journal-id><journal-id journal-id-type="publisher-id">JFCM</journal-id><journal-title-group><journal-title>Journal of Family &#x00026; Community Medicine</journal-title></journal-title-group><issn pub-type="ppub">1319-1683</issn><issn pub-type="epub">2229-340X</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25983604</article-id><article-id pub-id-type="pmc">4415133</article-id><article-id pub-id-type="publisher-id">JFCM-22-88</article-id><article-id pub-id-type="doi">10.4103/2230-8229.155380</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title><italic>Nigella sativa</italic>: A potential natural protective agent against cardiac dysfunction in patients with type 2 diabetes mellitus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bamosa</surname><given-names>Abdullah</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Kaatabi</surname><given-names>Huda</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Badar</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Al-Khadra</surname><given-names>Akram</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Al Elq</surname><given-names>Abdulmohsen</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Abou-Hozaifa</surname><given-names>Bodour</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lebda</surname><given-names>Fatma</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Al-Almaie</surname><given-names>Sameeh</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1"><italic>Department of Physiology, College of Medicine, University of Dammam, Dammam, Kingdom of Saudi Arabia</italic></aff><aff id="aff2"><label>1</label><italic>Department of Medicine, College of Medicine, University of Dammam, Dammam, Kingdom of Saudi Arabia</italic></aff><aff id="aff3"><label>2</label><italic>Department of Family Medicine, College of Medicine, University of Dammam, Dammam, Kingdom of Saudi Arabia</italic></aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Abdullah Bamosa, Department of Physiology, College of Medicine, University of Dammam, Dammam, Kingdom of Saudi Arabia. E-mail: <email xlink:href="bamosa@uod.edu.sa">bamosa@uod.edu.sa</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Aug</season><year>2015</year></pub-date><volume>22</volume><issue>2</issue><fpage>88</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright: &#x000a9; Journal of Family and Community Medicine</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objectives:</title><p>To study the effect of <italic>Nigella sativa</italic> supplementation on cardiac functions in Type 2 diabetic patients treated with oral hypoglycemic agents.</p></sec><sec id="st2"><title>Background:</title><p>Diabetes mellitus is associated with a high risk of cardiovascular morbidity and mortality. A number of reported beneficial effects of <italic>N. sativa</italic> on cardiovascular function were the inspiration for this study.</p></sec><sec id="st3"><title>Materials and Methods:</title><p>Sixty patients with uncontrolled diabetes (hemoglobin A<sub>1c</sub> [HbA<sub>1c</sub>] &#x0003e;7%) and with no known cardiovascular complications were recruited from the outpatient diabetes clinic. They were assigned, by convenience, to two groups; the control group received activated charcoal as placebo while the test group received 2 g/day of powdered <italic>N. sativa</italic> for 1-year. All patients continued with their standard oral hypoglycemic agents. Echocardiography was used to evaluate the diastolic function, systolic function, and left ventricular mass (LVM) before the intervention and after 6 and 12 months of the treatment.</p></sec><sec id="st4"><title>Results:</title><p>HbA<sub>1c</sub> decreased significantly in the <italic>N. sativa</italic> group but did not change in the control group. Echocardiographic assessment in the control group showed impairment in diastolic function after 12 months, but there were no significant changes in fractional shortening (FS) or ejection fraction (EF). Furthermore, left ventricular (LV) dimensions at diastole and systole, LVM, and LVM index were significantly increased. In <italic>N. sativa</italic> group, no significant changes were found in diastolic function or LVM. LV dimension at systole was decreased while FS and EF were significantly increased after 6 and 12 months.</p></sec><sec id="st5"><title>Conclusion:</title><p>N. sativa supplementation may protect the hearts of type 2 diabetic patients from diastolic dysfunction while improving LV systolic function.</p></sec></abstract><kwd-group><kwd>Diabetes mellitus</kwd><kwd>diastolic function</kwd><kwd>echocardiography</kwd><kwd>left ventricular mass</kwd><kwd>Nigella sativa</kwd><kwd>systolic function</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Diabetes mellitus (DM) is a chronic metabolic disorder caused by a defect in insulin secretion, insulin action, or both. The prevalence of DM is growing rapidly. According to the latest International Diabetes Federation (IDF) data, the worldwide prevalence of DM in 2012 was 371 million, and it is projected to reach 552 million by the year 2030. Studies have also indicated that the current prevalence of diabetes in the Arab world is among the 10 highest in the world.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] Patients with diabetes are at an increased risk of cardiovascular disease, and DM adds to the impact of other atherosclerosis risk factors such as dyslipidemia and hypertension for the prediction of cardiovascular manifestations.[<xref rid="ref3" ref-type="bibr">3</xref>] It was estimated that 4.8 million people died as a result of diabetes in 2012, and cardiovascular complications were the most common cause of the death of those patients.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] Cardiomyopathy characterized by an early diastolic and late systolic dysfunction is another manifestation of cardiac complications in patients with diabetes.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>]</p><p>Nigella sativa (<italic>N. sativa</italic>) has been reported to possess hypoglycemic,[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] hypolipidemic,[<xref rid="ref10" ref-type="bibr">10</xref>] and antioxidant properties.[<xref rid="ref11" ref-type="bibr">11</xref>] Hypotensive and diuretic effects of <italic>N. sativa</italic> have been reported in spontaneously hypertensive rats.[<xref rid="ref12" ref-type="bibr">12</xref>] It was also reported to induce homogenous physiologic cardiac hypertrophy with increased inotropic effect in rats.[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] Despite several published studies, there is still a gap in the information on the effect of <italic>N. sativa</italic> on human hearts and specifically the hearts of diabetics. With this background, the objective of this study was to explore the effects of a 1-year supplementation with <italic>N. sativa</italic> on cardiac function, evaluated by echocardiography, in uncontrolled type 2 diabetic patients treated with oral hypoglycemic agents.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>This was a phase 2 participant blinded placebo-controlled clinical trial, carried out at the College of Medicine, University of Dammam, Kingdom of Saudi Arabia, from May 2009 to December 2011. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The study was approved by the local ethical research committee of the University of Dammam and registered in the clinical trial registry&#x02013; India, under the reference no. CTRI/2013/06/003781.</p><p>We calculated a sample size of 24 for each group assuming the probability of Type I error (&#x003b1;) to be 0.05, Power (1-&#x003b2;) to be 0.8, paired difference to be detected as 0.6 and expected standard deviation (SD) of difference to be 1.00. However, assuming from previous experience that there would be about 15% dropout or failure to follow-up, we increased the sample size to 30 for each group.</p><p>Sixty patients with type 2 diabetes of both genders were recruited from the outpatient diabetes clinic of King Fahd Hospital of the University-Al Khobar and its affiliated primary health care center. The inclusion criteria were uncontrolled type 2 DM (based on two consecutive readings 3 months apart of hemoglobin A<sub>1c</sub> [HbA<sub>1c</sub>] of &#x0003e;7%), aged between 18 and 60 years, using standard oral hypoglycemic drugs regularly and consenting for intervention and regular follow-up. Patients with HbA<sub>1c</sub> &#x0003e;9%, treated with insulin therapy, with a body mass index (BMI) of &#x02265;40 kg/m<sup>2</sup> or with known cardiovascular diseases (coronary artery disease, valvular heart diseases, and heart failure), uncontrolled hypertension or nephropathy were excluded from the study.</p><p>For convenience, based on patients with lower HbA<sub>1c</sub> assigned to the placebo group, the patients were divided into two equal groups (<italic>n</italic> = 30 each), the control group (received placebo) and the test group (received <italic>N. sativa</italic>). The rationale for this division was to minimize the number of patients in the placebo group exceeding HbA<sub>1c</sub> of 9, in the 1-year treatment period, which would increase the dropout from the study.</p><p>Two visits at the 6<sup>th</sup> and 12<sup>th</sup> months were scheduled for a general follow-up after the initial visit. Patients were also contacted by phone every month in between the scheduled visits to check for compliance to their medications and any untoward effects.</p><p>
<list list-type="alpha-lower"><list-item><p><italic>N. sativa</italic> seed powder in the form of 500 mg capsules (BioExtract [Pvt.] Ltd., Srilanka) was used in a dose of 2 g/day in two divided doses. Dose selection was based on a previous study by our group[<xref rid="ref8" ref-type="bibr">8</xref>]</p></list-item><list-item><p>Activated charcoal capsules (260 mg) similar in size and color to the capsules of <italic>N. sativa</italic> (Arkopharma Pharmaceutical Laboratories Carros, France) were used as placebo and given 2 h before the standard oral hypoglycemic drugs, in two divided doses/day. In addition, the patients in both groups continued to use their regular standard oral hypoglycemic drugs.</p></list-item></list>
</p><p>Baseline data including age, gender, and duration of diabetes were recorded during the initial visit. Blood pressure, radial pulse rate, BMI, and HbA<sub>1c</sub> were measured prior to treatment and in each follow-up visit.</p><p>Echocardiogram was done at baseline and repeated at 6<sup>th</sup> and 12<sup>th</sup> months of follow-up. These measurements were performed in the same cardiac laboratory and interpreted by the same cardiologist. All patients underwent routine echocardiography using commercially available cardiac ultrasound diagnostic equipment (Toshiba Xario) with a 3 MHz transducer. Echocardiograms were obtained in the left lateral position at the end of expiration.[<xref rid="ref15" ref-type="bibr">15</xref>] The following measurements were obtained in two-dimensional guided M-mode, and at the end of both diastole and systole: End-diastolic left ventricular internal dimension (LVIDd), end-systolic left ventricular internal dimensions (LVIDs), end-diastolic interventricular septal wall thickness (IVSd), end-diastolic left ventricular posterior wall thickness (LVPWd).</p><p>Left ventricular mass (LVM) and corrected LVM (LVMc) were calculated according to the following:[<xref rid="ref16" ref-type="bibr">16</xref>]</p><p>LVM = 1.04 {(LVIDd + IVSd + LVPWd)<sup>3</sup>&#x02212;(LVIDd)<sup>3</sup>} (g).</p><p>LVMc = 0.8 (LVM) +0.6 (g)</p><p>This was indexed to body surface area (BSA) as follows: Left ventricle mass index (LVMI) = Corrected ventricle mass/BSA (g/m<sup>2</sup>).[<xref rid="ref17" ref-type="bibr">17</xref>]</p><p>For LV diastolic function, pulse wave Doppler was used to measure E/A ratio (the ratio of left ventricle early filling phase velocity, E, to late filling phase velocity, A, at the tip of mitral valve leaflets). Left atrial volume indexed to BSA (LAVI) was used to confirm the changes in E/A ratio and to differentiate between type 2 diastolic dysfunction and the pseudo normalization pattern of E/A ratio.</p><p>LAVI was calculated as based on cube method[<xref rid="ref18" ref-type="bibr">18</xref>] as follows:</p><p>Left atrial volume = &#x003c0; (constant) &#x000d7; (atrial dimension in cm)<sup>3/</sup> 6</p><p>LAV = 3.14159265 &#x000d7; D<sup>3/</sup> 6</p><p>LAVI = LAV/BSA= (cm<sup>3</sup>/m<sup>2</sup>)</p><p>LV systolic function was assessed by end-systolic LV internal dimension and by both fractional shorting (FS) and ejection fraction (EF) of the left ventricle.</p><p>Statistical analysis was performed using the Statistical Package of Social Science (SPSS) version 16 (SPSS Inc. Released 2007. SPSS for Windows, Version 16.0. Chicago, SPSS Inc). Data are presented as means &#x000b1; SD. In each group, readings were compared to their corresponding baseline values using Student's <italic>t</italic>-test for paired data. Results in the two groups were compared using Student's <italic>t</italic>-test for unpaired data. <italic>P</italic> &#x0003c;0.05 was considered as significant.</p></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p><xref ref-type="table" rid="T1">Table 1</xref> shows the comparison of baseline data between the placebo (control) and <italic>N. sativa</italic> Groups. The demographic and pretreatment baseline data of all patients in the two groups did not differ significantly, except for HbA<sub>1c</sub>, which was higher in the <italic>N. sativa</italic> group than the controls. All patients in the <italic>N. sativa</italic> group tolerated the treatment and showed no adverse effects throughout the study period.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Comparison of baseline data between the placebo group (control) and <italic>N. sativa</italic> groups</p></caption><graphic xlink:href="JFCM-22-88-g001"/></table-wrap><p><xref ref-type="table" rid="T2">Table 2</xref> shows changes in echocardiographic measurements of diastolic and systolic functions. E/A ratio was decreased in the placebo group in both readings. This decrease was only significant at 12<sup>th</sup> month reading (<italic>P</italic> &#x0003c; 0.05). However, the <italic>N. sativa</italic> group did not show any decrease in E/A ratio. On the contrary, the ratio insignificantly increased. There was no significant change in LAVI in both the groups. As regards the parameters of systolic function, LVIDs at 6<sup>th</sup> month was significantly increased in the placebo group (<italic>P</italic> &#x0003c; 0.05), while it was significantly decreased in <italic>N. sativa</italic> group at both 6<sup>th</sup> (<italic>P</italic> &#x0003c; 0.05) and 12<sup>th</sup> (<italic>P</italic> &#x0003c; 0.01) months. Interestingly, there was a significant improvement in both FS% and EF% in <italic>N. sativa</italic> group, unlike the placebo group.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparison of echocardiographic parameters of cardiac diastolic and systolic function at 6 months and 12 months after treatment with their corresponding baseline values in the control and <italic>Nigella sativa</italic> groups</p></caption><graphic xlink:href="JFCM-22-88-g002"/></table-wrap><p><xref ref-type="table" rid="T3">Table 3</xref> illustrates changes in echocardiographic measurements of left ventricular (LV) internal dimensions and mass at different treatment durations in both the groups. LVIDd increased significantly (<italic>P</italic> &#x0003c; 0.05) in the control group both at 6<sup>th</sup> and 12<sup>th</sup> months. This increase was, however, not seen in the <italic>N. sativa</italic> group. There was no significant change in LVPWd or IVSd in any reading in both groups. However, the reading at 6 months for both LVMc and LVMI were significantly (<italic>P</italic> &#x0003c; 0.05) increased in the Control group, but not in the <italic>N. sativa</italic> group.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Changes in echocardiographic measurements of LV internal dimensions at different treatment durations in the control group and <italic>N. sativa</italic> group compared to their corresponding baseline values</p></caption><graphic xlink:href="JFCM-22-88-g003"/></table-wrap><p><xref ref-type="table" rid="T4">Table 4</xref> demonstrates a comparison of all the echocardiographic parameters between the control group and <italic>N. sativa</italic> group at the baseline, 6 months and 12 months after initiation of treatment. There was no significant difference in any baseline reading for all echocardiographic parameters evaluated. LVIDs at 6<sup>th</sup> month were significantly (<italic>P</italic> &#x0003c; 0.05) less in the <italic>N. sativa</italic> group. FS(%) was significantly more in the <italic>N. sativa</italic> group both at 6<sup>th</sup> (<italic>P</italic> &#x0003c; 0.01) and 12<sup>th</sup> (<italic>P</italic> &#x0003c; 0.05) months while EF(%) was significantly (<italic>P</italic> &#x0003c; 0.01) higher in the <italic>N. sativa</italic> group at the 6<sup>th</sup> month reading only.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Comparison of echocardiographic measurements of diastolic function, systolic function, and LV internal dimensions</p></caption><graphic xlink:href="JFCM-22-88-g004"/></table-wrap><p><xref ref-type="table" rid="T5">Table 5</xref> shows a comparison of BMI, HbA<sub>1c</sub>, pulse rate and mean arterial pressure (MAP) between baseline, 6 months and 12 months for both the groups. HbA<sub>1c</sub> was reduced in the <italic>N. sativa</italic> group at both follow-ups; but, this reduction was only significant at 12 months (<italic>P</italic> &#x0003c; 0.05). Pulse rate was significantly (<italic>P</italic> &#x0003c; 0.05) reduced at 12 months follow-up in the <italic>N. sativa</italic> group. MAP was significantly (<italic>P</italic> &#x0003c; 0.05) reduced at both the 6<sup>th</sup> month and 12<sup>th</sup> month follow-up in the <italic>N. sativa</italic> group.</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Changes in baseline measurements at different treatment durations in the placebo and <italic>N. sativa</italic> group compared to their corresponding baseline values</p></caption><graphic xlink:href="JFCM-22-88-g005"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>A review of the literature shows that the current study is the first to examine the effects of <italic>N. sativa</italic> on cardiac functions in patients with type 2 DM. The results indicated potential protective effects of <italic>N. sativa</italic> on cardiac diastolic and systolic functions and LVM in diabetic patients. <italic>N. sativa</italic> supplementation tended to prevent diastolic dysfunction as well as improve systolic function. In addition, it showed a trend of preventing an increase in the LVM.</p><p>Cardiac dysfunction in patients with DM manifests as diabetic cardiomyopathy that is characterized by an early diastolic and late systolic dysfunction.[<xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] Diastolic dysfunction has been reported in diabetic animals[<xref rid="ref19" ref-type="bibr">19</xref>] as well as diabetic patients.[<xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref>] Transmitral flow (E/A) ratio as a marker of diastolic dysfunction has been found to be impaired in diabetic patients without overt cardiovascular disease.[<xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref>] In this study, the placebo group showed a trend towards diastolic dysfunction, as E/A ratio was significantly decreased at the end of the study, while in <italic>N. sativa</italic> group, the diastolic function was preserved. This may imply a protective role of <italic>N. sativa</italic> against diastolic dysfunction in diabetic patients.</p><p>Left ventricular systolic dysfunction has been linked to DM as a late manifestation of diabetic cardiomyopathy.[<xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref25" ref-type="bibr">25</xref>] Interestingly, in the current study, <italic>N. sativa</italic> supplementation for 1-year improved systolic function manifested by a significant decrease in LVIDs, and a significant increase in both FS% and EF% compared to their baseline readings and to the corresponding control group values. Studies on cardiac contractility in experimental rat models fed with <italic>N. sativa</italic> for 2 months resulted in a positive inotropic effect manifested as better contractility,[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] which supports our findings in the <italic>N. sativa</italic> treated group. In contrast to our results, Boskabady <italic>et al</italic>.[<xref rid="ref26" ref-type="bibr">26</xref>] reported a potent inhibitory effect on the muscle contractility of guinea pig isolated heart produced by perfusing the myocardium with <italic>N. sativa</italic> extract. However, since we have investigated the effect of <italic>N. sativa</italic> supplementation on cardiac parameters, our study is closer to that of the first group of researchers[<xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] who reported enhanced cardiac performance than the Boskabady group. Therefore, it is likely that the direct effect of <italic>N. sativa</italic> on cardiac muscle fibers is inhibitory, while long-term ingestion of <italic>N. sativa</italic> may lead to structural and/or functional myocardial modifications that enhance cardiac performance.</p><p>Previous studies have demonstrated that LV hypertrophy occurs in patients with type 2 DM independent of hypertension or coronary artery disease.[<xref rid="ref27" ref-type="bibr">27</xref>] In diabetic rats, LV hypertrophy was found to be associated with increased left ventricle internal dimensions in both diastole and systole.[<xref rid="ref28" ref-type="bibr">28</xref>] Likewise, in the current study, both LVID in systole and diastole were increased significantly in the placebo group compared to their baseline values. LVMc was also increased in this group. However, this increment in LVMc was not associated with a parallel increment in the posterior wall thickness (LVPWd) or interventricular septum thickness (IVSd), which indicates that this increase may be due to the increase in LV internal dimensions. In contrast, a previous study on elderly individuals (&#x02265;65 years) reported that increased LVM in diabetics was associated with a greater interventricular septum and left posterior wall thicknesses rather than in dimensions when compared to nondiabetic patients.[<xref rid="ref29" ref-type="bibr">29</xref>] However, the age of the patients in that study was much higher (&#x02265;65 years) than our patients age (mean age 46.9), which might explain this difference. Indeed, it has been reported that LVM age coefficient in diabetic women was significantly higher than the estimate for nondiabetics.[<xref rid="ref30" ref-type="bibr">30</xref>] Interestingly, in the test group, <italic>N. sativa</italic> supplementation tended to prevent such an increase in ventricular mass and ventricular dimensions.</p><p>Felicio <italic>et al</italic>.[<xref rid="ref31" ref-type="bibr">31</xref>] reported reductions in LVM index associated with a fall in blood glucose while the mass index increased in those who did not achieve glycemic control. In addition, a close relationship was found between glycemic control and improvement in LV diastolic[<xref rid="ref32" ref-type="bibr">32</xref>] and systolic[<xref rid="ref33" ref-type="bibr">33</xref>] functions. Therefore, the beneficial effects of <italic>N. sativa</italic> on cardiac parameters, encountered in our study, might be partly due to the improvement in glycemic control in these diabetic patients. Indeed, a study on newly diagnosed diabetic patients showed a significant improvement in cardiac functions after 15 months of better glycemic control in these patients.[<xref rid="ref34" ref-type="bibr">34</xref>]</p><p>The improvement in blood pressure observed in the <italic>N. sativa</italic> group, compared to their baseline values, is consistent with our recent report on the short-term effect of <italic>N. sativa</italic> in diabetic patients.[<xref rid="ref35" ref-type="bibr">35</xref>] Other human studies have also demonstrated the hypotensive effect of <italic>N. sativa</italic> in patients with mild hypertension[<xref rid="ref36" ref-type="bibr">36</xref>] and those with central obesity.[<xref rid="ref37" ref-type="bibr">37</xref>]</p><p>Limitations of this study include small sample size, aggravated by the loss of some patients who did not turn up for follow-up, and the relatively short duration of the intervention. Further studies on a larger sample size in a longer duration utilizing advanced echocardiography techniques such as tissue Doppler, might confirm these promising effects of <italic>N. sativa</italic> on the heart and explore possible mechanisms.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>The present study indicates the potential beneficial effects of a 1-year supplementation of <italic>N. sativa</italic> in protecting the hearts of type 2 diabetic patients against diastolic dysfunction and left ventricle mass increment, and improving systolic function.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>This study was supported by University of Dammam and King Abdulazizi City for science and technology.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="book"><article-title>International Diabetes Federation. IDF Diabetes Atlas</article-title><year>2011</year><date-in-citation>Last accessed on 2014 Sep 11</date-in-citation><edition>5th ed</edition><publisher-loc>Brussels, Belgium</publisher-loc><publisher-name>International Diabetes Federation</publisher-name><comment>Available from:
<uri xlink:type="simple" xlink:href="http://www.idf.org/diabetesatlas/5e/Update2012">http://www.idf.org/diabetesatlas/5e/Update2012</uri></comment></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhyas</surname><given-names>L</given-names></name><name><surname>McKay</surname><given-names>A</given-names></name><name><surname>Majeed</surname><given-names>A</given-names></name></person-group><article-title>Prevalence of type 2 diabetes in the States of the co-operation council for the Arab States of the Gulf: A systematic review</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e40948</fpage><pub-id pub-id-type="pmid">22905094</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Reusch</surname><given-names>JE</given-names></name></person-group><article-title>Diabetes and cardiovascular disease: Changing the focus from glycemic control to improving long-term survival</article-title><source>Am J Cardiol</source><year>2012</year><volume>110</volume><issue>9 Suppl</issue><fpage>58B</fpage><lpage>68</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>OE</given-names></name><name><surname>Birkeland</surname><given-names>KI</given-names></name></person-group><article-title>Preventing macrovascular disease in patients with type 2 diabetes mellitus</article-title><source>Am J Cardiovasc Drugs</source><year>2003</year><volume>3</volume><fpage>283</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">14728081</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wannamethee</surname><given-names>SG</given-names></name><name><surname>Shaper</surname><given-names>AG</given-names></name><name><surname>Lennon</surname><given-names>L</given-names></name></person-group><article-title>Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease</article-title><source>Heart</source><year>2004</year><volume>90</volume><fpage>1398</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">15547012</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarquini</surname><given-names>R</given-names></name><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Pala</surname><given-names>L</given-names></name><name><surname>Rotella</surname><given-names>CM</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name></person-group><article-title>The diabetic cardiomyopathy</article-title><source>Acta Diabetol</source><year>2011</year><volume>48</volume><fpage>173</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">20198391</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>BN</given-names></name><name><surname>Morais</surname><given-names>S</given-names></name><name><surname>Cubbon</surname><given-names>RM</given-names></name><name><surname>Kearney</surname><given-names>MT</given-names></name></person-group><article-title>Diabetes mellitus and the heart</article-title><source>Int J Clin Pract</source><year>2012</year><volume>66</volume><fpage>640</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22698416</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamosa</surname><given-names>AO</given-names></name><name><surname>Kaatabi</surname><given-names>H</given-names></name><name><surname>Lebdaa</surname><given-names>FM</given-names></name><name><surname>Elq</surname><given-names>AM</given-names></name><name><surname>Al-Sultanb</surname><given-names>A</given-names></name></person-group><article-title>Effect of <italic>Nigella sativa</italic> seeds on the glycemic control of patients with type 2 diabetes mellitus</article-title><source>Indian J Physiol Pharmacol</source><year>2010</year><volume>54</volume><fpage>344</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">21675032</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohtashami</surname><given-names>R</given-names></name><name><surname>Amini</surname><given-names>M</given-names></name><name><surname>Huseini</surname><given-names>FH</given-names></name><name><surname>Ghamarchehre</surname><given-names>M</given-names></name><name><surname>Sadeghi</surname><given-names>Z</given-names></name><name><surname>Hajjagaee</surname><given-names>R</given-names></name><etal/></person-group><article-title>Blood glucose lowering effects of <italic>Nigella sativa</italic> L. seeds oil in healthy volunteers: A randomized, double-blind, placebo-controlled clinical trial</article-title><source>J Med Plants</source><year>2011</year><volume>10</volume><fpage>90</fpage><lpage>4</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kocyigit</surname><given-names>Y</given-names></name><name><surname>Atamer</surname><given-names>Y</given-names></name><name><surname>Uysal</surname><given-names>E</given-names></name></person-group><article-title>The effect of dietary supplementation of <italic>Nigella sativa</italic> L. on serum lipid profile in rats</article-title><source>Saudi Med J</source><year>2009</year><volume>30</volume><fpage>893</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19618002</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaleem</surname><given-names>M</given-names></name><name><surname>Kirmani</surname><given-names>D</given-names></name><name><surname>Asif</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>Q</given-names></name><name><surname>Bano</surname><given-names>B</given-names></name></person-group><article-title>Biochemical effects of <italic>Nigella</italic> sativa L seeds in diabetic rats</article-title><source>Indian J Exp Biol</source><year>2006</year><volume>44</volume><fpage>745</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16999030</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaoui</surname><given-names>A</given-names></name><name><surname>Cherrah</surname><given-names>Y</given-names></name><name><surname>Lacaille-Dubois</surname><given-names>MA</given-names></name><name><surname>Settaf</surname><given-names>A</given-names></name><name><surname>Amarouch</surname><given-names>H</given-names></name><name><surname>Hassar</surname><given-names>M</given-names></name></person-group><article-title>Diuretic and hypotensive effects of <italic>Nigella sativa</italic> in the spontaneously hypertensive rat</article-title><source>Therapie</source><year>2000</year><volume>55</volume><fpage>379</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">10967716</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Bahai</surname><given-names>MN</given-names></name><name><surname>Al-Hariri</surname><given-names>MT</given-names></name><name><surname>Yar</surname><given-names>T</given-names></name><name><surname>Bamosa</surname><given-names>AO</given-names></name></person-group><article-title>Cardiac inotropic and hypertrophic effects of Nigella sativa supplementation in rats</article-title><source>Int J Cardiol</source><year>2009</year><volume>131</volume><fpage>e115</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17931720</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yar</surname><given-names>T</given-names></name><name><surname>El-Hariri</surname><given-names>M</given-names></name><name><surname>El-Bahai</surname><given-names>MN</given-names></name><name><surname>Bamosa</surname><given-names>AO</given-names></name></person-group><article-title>Effects of <italic>Nigella sativa</italic> supplementation for one month on cardiac reserve in rats</article-title><source>Indian J Physiol Pharmacol</source><year>2008</year><volume>52</volume><fpage>141</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19130857</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahn</surname><given-names>DJ</given-names></name><name><surname>DeMaria</surname><given-names>A</given-names></name><name><surname>Kisslo</surname><given-names>J</given-names></name><name><surname>Weyman</surname><given-names>A</given-names></name></person-group><article-title>Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements</article-title><source>Circulation</source><year>1978</year><volume>58</volume><fpage>1072</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">709763</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallerson</surname><given-names>DC</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name></person-group><article-title>Reproducibility of echocardiographic left ventricular measurements</article-title><source>Hypertension</source><year>1987</year><volume>9</volume><fpage>II6</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">3542819</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foppa</surname><given-names>M</given-names></name><name><surname>Duncan</surname><given-names>BB</given-names></name><name><surname>Rohde</surname><given-names>LE</given-names></name></person-group><article-title>Echocardiography-based left ventricular mass estimation. How should we define hypertrophy?</article-title><source>Cardiovasc Ultrasound</source><year>2005</year><volume>3</volume><fpage>17</fpage><pub-id pub-id-type="pmid">15963236</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schabelman</surname><given-names>S</given-names></name><name><surname>Schiller</surname><given-names>NB</given-names></name><name><surname>Silverman</surname><given-names>NH</given-names></name><name><surname>Ports</surname><given-names>TA</given-names></name></person-group><article-title>Left atrial volume estimation by two-dimensional echocardiography</article-title><source>Cathet Cardiovasc Diagn</source><year>1981</year><volume>7</volume><fpage>165</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">7296665</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semeniuk</surname><given-names>LM</given-names></name><name><surname>Kryski</surname><given-names>AJ</given-names></name><name><surname>Severson</surname><given-names>DL</given-names></name></person-group><article-title>Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2002</year><volume>283</volume><fpage>H976</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12181126</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajan</surname><given-names>SK</given-names></name><name><surname>Gokhale</surname><given-names>SM</given-names></name></person-group><article-title>Cardiovascular function in patients with insulin-dependent diabetes mellitus: A study using noninvasive methods</article-title><source>Ann N Y Acad Sci</source><year>2002</year><volume>958</volume><fpage>425</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">12021155</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galderisi</surname><given-names>M</given-names></name></person-group><article-title>Diastolic dysfunction and diabetic cardiomyopathy: Evaluation by Doppler echocardiography</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>1548</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17045886</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>NR</given-names></name><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Karki</surname><given-names>P</given-names></name><name><surname>Shrestha</surname><given-names>NK</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name></person-group><article-title>Echocardiographic evaluation of diastolic function in asymptomatic type 2 diabetes</article-title><source>JNMA J Nepal Med Assoc</source><year>2009</year><volume>48</volume><fpage>20</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">19529053</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faden</surname><given-names>G</given-names></name><name><surname>Faganello</surname><given-names>G</given-names></name><name><surname>De Feo</surname><given-names>S</given-names></name><name><surname>Berlinghieri</surname><given-names>N</given-names></name><name><surname>Tarantini</surname><given-names>L</given-names></name><name><surname>Di Lenarda</surname><given-names>A</given-names></name><etal/></person-group><article-title>The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: Data from the SHORTWAVE study</article-title><source>Diabetes Res Clin Pract</source><year>2013</year><volume>101</volume><fpage>309</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">23886659</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnl&#x000f6;v</surname><given-names>J</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name><name><surname>Zethelius</surname><given-names>B</given-names></name><name><surname>Andr&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Hales</surname><given-names>CN</given-names></name><name><surname>Vessby</surname><given-names>B</given-names></name><etal/></person-group><article-title>Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up</article-title><source>Am Heart J</source><year>2001</year><volume>142</volume><fpage>720</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">11579365</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cioffi</surname><given-names>G</given-names></name><name><surname>Giorda</surname><given-names>CB</given-names></name><name><surname>Chinali</surname><given-names>M</given-names></name><name><surname>Lenarda</surname><given-names>AD</given-names></name><name><surname>Faggiano</surname><given-names>P</given-names></name><name><surname>Lucci</surname><given-names>D</given-names></name><etal/></person-group><article-title>Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: The DYDA study</article-title><source>Diabetes Res Clin Pract</source><year>2013</year><volume>101</volume><fpage>236</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">23806478</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boskabady</surname><given-names>MH</given-names></name><name><surname>Shafei</surname><given-names>MN</given-names></name><name><surname>Parsaee</surname><given-names>H</given-names></name></person-group><article-title>Effects of aqueous and macerated extracts from <italic>Nigella sativa</italic> on guinea pig isolated heart activity</article-title><source>Pharmazie</source><year>2005</year><volume>60</volume><fpage>943</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16398273</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutale</surname><given-names>JJ</given-names></name><name><surname>Thordarson</surname><given-names>H</given-names></name><name><surname>Gulam-Abbas</surname><given-names>Z</given-names></name><name><surname>Vetvik</surname><given-names>K</given-names></name><name><surname>Gerdts</surname><given-names>E</given-names></name></person-group><article-title>Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania</article-title><source>Cardiovasc J Afr</source><year>2008</year><volume>19</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">18320079</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struthers</surname><given-names>AD</given-names></name><name><surname>Morris</surname><given-names>AD</given-names></name></person-group><article-title>Screening for and treating left-ventricular abnormalities in diabetes mellitus: A new way of reducing cardiac deaths</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>1430</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">11978359</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Gardin</surname><given-names>JM</given-names></name><name><surname>Lynch</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>VE</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Savage</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: The Cardiovascular Health Study</article-title><source>Am Heart J</source><year>1997</year><volume>133</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">9006288</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galderisi</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>KM</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name></person-group><article-title>Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study)</article-title><source>Am J Cardiol</source><year>1991</year><volume>68</volume><fpage>85</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">2058564</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felicio</surname><given-names>JS</given-names></name><name><surname>Ferreira</surname><given-names>SR</given-names></name><name><surname>Plavnik</surname><given-names>FL</given-names></name><name><surname>Mois&#x000e9;s</surname><given-names>V</given-names></name><name><surname>Kohlmann</surname><given-names>O</given-names><suffix>Jr</suffix></name><name><surname>Ribeiro</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus</article-title><source>Am J Hypertens</source><year>2000</year><volume>13</volume><fpage>1149</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11078173</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarnert</surname><given-names>C</given-names></name><name><surname>Landstedt-Hallin</surname><given-names>L</given-names></name><name><surname>Malmberg</surname><given-names>K</given-names></name><name><surname>Melcher</surname><given-names>A</given-names></name><name><surname>Ohrvik</surname><given-names>J</given-names></name><name><surname>Persson</surname><given-names>H</given-names></name><etal/></person-group><article-title>A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: A report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study</article-title><source>Eur J Heart Fail</source><year>2009</year><volume>11</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">19147455</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>MC</given-names></name></person-group><article-title>Type 2 diabetes and chronic systolic heart failure: Clinical implications</article-title><source>J Cardiovasc Nurs</source><year>2004</year><volume>19</volume><fpage>S35</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">15529072</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanninen</surname><given-names>E</given-names></name><name><surname>Mustonen</surname><given-names>J</given-names></name><name><surname>Vainio</surname><given-names>P</given-names></name><name><surname>L&#x000e4;nsimies</surname><given-names>E</given-names></name><name><surname>Uusitupa</surname><given-names>M</given-names></name></person-group><article-title>Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus</article-title><source>Am J Cardiol</source><year>1992</year><volume>70</volume><fpage>371</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1632406</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebda</surname><given-names>FM</given-names></name><name><surname>Bamosa</surname><given-names>AO</given-names></name><name><surname>Kaatabi</surname><given-names>H</given-names></name><name><surname>Al-Elq</surname><given-names>A</given-names></name><name><surname>Al-sultan</surname><given-names>A</given-names></name></person-group><article-title>Effect of <italic>Nigella sativa</italic> on hemodynamics, hemoglobin, and blood coagulation in patients with type 2 diabetes</article-title><source>Egypt J Haematol</source><year>2012</year><volume>37</volume><fpage>73</fpage><lpage>80</lpage></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehkordi</surname><given-names>FR</given-names></name><name><surname>Kamkhah</surname><given-names>AF</given-names></name></person-group><article-title>Antihypertensive effect of Nigella <italic>sativa seed</italic> extract in patients with mild hypertension</article-title><source>Fundam Clin Pharmacol</source><year>2008</year><volume>22</volume><fpage>447</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">18705755</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datau</surname><given-names>EA</given-names></name><name><surname>Wardhana</surname></name><name><surname>Surachmanto</surname><given-names>EE</given-names></name><name><surname>Pandelaki</surname><given-names>K</given-names></name><name><surname>Langi</surname><given-names>JA</given-names></name><name><surname>Fias</surname></name></person-group><article-title>Efficacy of <italic>Nigella sativa</italic> on serum free testosterone and metabolic disturbances in central obese male</article-title><source>Acta Med Indones</source><year>2010</year><volume>42</volume><fpage>130</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">20724766</pub-id></element-citation></ref></ref-list></back></article>